Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$11.59 - $16.7 $172,053 - $247,911
14,845 New
14,845 $199,000
Q2 2022

Aug 11, 2022

BUY
$8.7 - $20.18 $299,158 - $693,909
34,386 New
34,386 $376,000

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $58.8M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Seven Grand Managers, LLC Portfolio

Follow Seven Grand Managers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Grand Managers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seven Grand Managers, LLC with notifications on news.